REFERENCES

• Bárány P, et al. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29
• Boaz M, et al. Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356
• Bucharles S, et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Renal Nutr. 2012;22
• Chang JW, et al. Effects of alpha-lipoic acid on plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol. 2007;27
• Delanaye P, et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant. 2013;28
• Himmelfarb J, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end stage renal disease. Kidney Int. 2003;64
• Icardi A, et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013;28
• Jiang Q, et al. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A. 2000;97
• Jun M, et al. Antioxidants for chronic kidney disease (review). The Cochrane Library. 2012;10
• Khabbazi T, et al. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J Renal Nutr. 2012;22
• Matias PJ, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5
• Mucsi I, et al. Abstract ASN09L1_3200a (2000) Proc. Natl. Acad. Sci. USA 97 11494-11499.
• Mune M, et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int. 1999;71(suppl)
• Paul SK, et al. Effect of cholecalciferol on proteinuria in patients with chronic kidney disease [Abstract TH-PO191]. Annual Meeting of the American Society of Nephrology; Atlanta, GA; November 5-10, 2013
• Sharma A, et al. Effects of a novel multivitamin antioxidant nutraceutical in chronic kidney disease patients on hemodialysis: a prospective trial [Abstract 282, National Kidney Foundation Spring Clinical Meetings]. Am J Kidney Dis. 2011;57
• Smith JP, et al. Dialysis Outcomes and Practice Patients Study Group. American Society of Nephrology, 2010. Poster
• Suh SH, et al. Alpha-lipoic acid attenuates lipopolysaccharide-induced kidney injury [Abstract FR-PO064]. Annual Meeting of the American Society of Nephrology; Atlanta, GA; November 5-10, 2013

BIBLIOGRAPHY

• Armas LAG, et al. Vitamin D: the iceberg nutrient. J Renal Nutr. 2011;21
• Aslam S. Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease? Curr Opin Nephrol Hypertens. 2008;17
• Bradbury BD, et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant. 2009;24
• Chan KE, et al. Facility factors dominate the ability to achieve target hemoglobin levels in hemodialysis patients. Nephrol Dial Transplant. 2008;23
• Chandra P, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14
• Cristol JP, et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant. 1997;12
• Del Vecchio L, et al. What we know about oxidative stress in patients with chronic kidney disease on dialysis—clinical effects, potential treatment, and prevention. Semin Dial. 2011;24
• Dursun B, et al. Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant. 2008;23
• El-Hennawy AS, et al. A selected controlled trial of supplementary vitamin E for treatment of muscle cramps in hemodialysis patients. Am J Ther. 2010;17
• Ferreira A, et al. Al Nephrology Hypertension, 2008
• Goicoechea M, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998;54
• Goldstein SL, et al. Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int. 2009;76
• Gunnell J, et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33
• Himmelfarb J, et al. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000;58
• Himmelfarb J, et al. The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62
• Kalantar-Zadeh K, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003;42
• Krasniak A, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007;22
• Liu Y. Advanced oxidation protein products: a causative link between oxidative stress and podocyte depletion. Kidney Int. 2009;76
• Locatelli F, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006;21
• Mafra D, et al. Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients. Nephrol Dial Transplant. 2009;24
• Mann JF, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int. 2004;65
• Menon V, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68
• Nanayakkara PW, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med. 2007;167
• Oberg BP, et al. Increased prevalence of oxidant disease. Kidney Int. 2004;65
• Rattanasompattikul M, et al. Association of malnutrition–inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013;28
• Ridker PM, et al. Novel risk factors for systemic atherosclerosis: a comparison of CRP, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285
• Roob JM, et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol. 2000;11
• Saab G, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007;105
• Sarnak MJ, et al. Serum C-reactive protein and diet in renal disease study. Kidney Int. 2002;62
• Schiffrin EL, et al. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116
• Shooley JC, et al. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol. 1987;67
• Stenvinkel P, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55
• Wanner C, et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002;80(suppl)
• Weiner DE, et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 2008;73
• Witko-Sarsat V, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161